Impact of Prophylactic Steroids on CAR T-cell Related Toxicity for Relapsed and Refractory Non-Hodgkin Lymphoma.
Preventive steroids in CAR-T lymphoma therapy appear to reduce severe side effects, pointing toward safer treatment protocols.
This PubMed-indexed study examined bACKGROUND: Anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The abstract reports prophylactic corticosteroid use increased after cohort 6 of ZUMA-1, which suggested reduced severe CRS and ICANS, although the lack of a comparator arm limits interpretation.
What the study was
- Study design
- Observational/Journal Article
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
Conservative triage based on the PubMed abstract: observational/journal article with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.